

Seasonal Respiratory Products Order Form for Hospitals, Physicians, Primary Care and Midwives

Mailing Address:

Niagara Region Public Health
1815 Sir Isaac Brock Way
P.O. Box 1052
Thorold, ON L2V 0A2
905-688-8248 Toll free: 1-888-505-6074 ext. 7396
niagararegion.ca

Complete and return this form by fax
to 905-688-4667 or email **vpd@niagararegion.ca**

Order No:

Program assistant
initials:

All vaccine orders require:

- A copy of your current 4 week fridge temperature log (up to present day)
- One calendar week prior to scheduled delivery date to fill the order.

Facility name:

Phone:

Ext:

Contact:

Date (mm/dd/yyyy):

Email:

Important reminders:

- All vaccine orders will be delivered to your facility according to the **vaccine delivery schedule** (niagararegion.ca/health/professionals/vaccine/vaccine-schedule.aspx)
- Orders will be filled based on product availability. Do not delay COVID-19 or influenza vaccination to wait for a particular product, especially since supply may be unpredictable.
- Do not schedule or plan any large immunization clinics for the general population until you have ordered and received sufficient vaccine supply
- Co-administration is encouraged to help mitigate the impacts of the respiratory season
- Refer to ongoing Public Health Communications (e.g. Memos, Pulse Newsletter, niagararegion.ca) for the most up-to-date information regarding the timing of and details for these programs (e.g. beginning and end of seasons, administration extensions, vaccine availability, eligibility, etc.)

COVID-19 Vaccine

Facility name:

Phone:

Ext:

Current COVID-19 vaccine providers must document doses administered according to the professional standards of practice by the administering professional. Documentation is expected to be completed in Panorama Guided Workflow (PGW) after its launch.

Vaccine may be moved in a frozen state from Public Health and will need to be thawed prior to administration. Never freeze COVID-19 vaccine after receiving your supply.

COVID-19 vaccine should not routinely be transported, except under exceptional circumstances based on a risk assessment, follow **Ministry of Health COVID-19 Vaccine Storage and Handling guidance (ontario.ca/page/covid-19-vaccine-program)**.

Vaccines	Trade Name	Doses on hand	Doses requested
COVID-19 Children 6 months to under 5 years old	Moderna Spikevax 25 mcg/0.25 mL ¹		
COVID-19 Children 5 to 11 years old	Moderna Spikevax 25 mcg/0.25 mL ¹ or Pfizer-BioNTech Comirnaty 10 mcg/0.3 mL		
COVID-19 12 years of age and older	Moderna Spikevax 50 mcg/0.5 mL ¹ or Pfizer-BioNTech Comirnaty 30 mcg/0.3 mL		

- Follow Ministry of Health guidance for fall 2026 and spring 2027 COVID-19 vaccine administration
- Refer to Ministry of Health immunization documents at **COVID-19 Vaccine Program (ontario.ca/page/covid-19-vaccine-program)**

1 The Moderna product is the same vaccine regardless of the patient's age. This means that age-appropriate doses can be drawn up from the same multi-dose vial.

Influenza Vaccine

Facility name:

Phone:

Ext:

Vaccines	Trade Name	Doses on hand	Doses requested
Standard-dose Trivalent (TIV) • 6 months of age and older	Fluzone®, Fluviral or Flucelvax®		
High-dose Trivalent (TIV-HD) or Adjuvanted Trivalent (TIV-adj) • 65 years of age and older	Fluzone® High-dose or Fluad®		

- If a child under 9 years of age is receiving the influenza vaccine for the first time, they require 2 doses 4 weeks apart
- Refer to **Universal Influenza Immunization Program** (ontario.ca/page/universal-influenza-immunization-program)

Respiratory Syncytial Virus (RSV) Products

Facility name:

Phone:

Ext:

Vaccines	Trade Name	Doses on hand	Doses requested
Monoclonal antibody (mAb) for infants and high-risk children	Beyfortus® 50 mg		
Monoclonal antibody (mAb) for infants and high-risk children	Beyfortus® 100 mg		
Vaccine for pregnant individuals Do not administer RSV vaccine to a pregnant individual who has already received a dose of RSV vaccine during a past pregnancy.	Abrysvo®		
Vaccine for • High-risk individuals 60 years of age and older • Individuals 75 years of age and older Adults who have received a previous RSV dose are not eligible to receive another publicly funded dose this season.	Abrysvo® or Arexvy®		

Refer to Ministry of Health fact sheets at Respiratory Syncytial Virus (RSV) prevention programs (ontario.ca/page/respiratory-syncytial-virus-rsv-prevention-programs).

Infant and high-risk children RSV prevention program:

- Beyfortus® is the primary product to protect infants and high-risk children from RSV. Dosing is dependent on the age and weight of the recipient.
- Administration of both Abrysvo® to the pregnant individual and Beyfortus® to the infant is not recommended except under specific circumstances
- End of the RSV season:
 - Beyfortus® and the maternal vaccine Abrysvo® should no longer be administered to infants, children, or pregnant individuals after the program wind-down has been communicated
 - All remaining non-expired inventory held at healthcare premises should be stored under appropriate cold chain for use during the next RSV season and not returned to Public Health